Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) presented new preclinical data for its prostate cancer candidate ATNM-400 at the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans.
The data shows ATNM-400, which uses the alpha-particle emitter Actinium-225, demonstrated superior cancer cell killing compared to Xtandi (enzalutamide) and greater efficacy than both Pluvicto (177Lu-PSMA-617) and Ac-225-PSMA-617 in laboratory and animal models.
According to the company’s statement, ATNM-400 targets a non-PSMA receptor that is implicated in prostate cancer progression and therapeutic resistance. The target protein continues to be expressed after treatment with androgen receptor inhibitors and PSMA radiotherapy.
Key findings showed ATNM-400 killed Xtandi-resistant prostate cancer cells that remained after Xtandi treatment. The therapy also demonstrated more effective tumor growth inhibition compared to both Pluvicto and 225Ac-PSMA-617 at therapeutically relevant doses.
"ATNM-400 is the ideal cornerstone of our emerging solid tumor pipeline," said Sandesh Seth, Actinium’s Chairman and CEO, in the press release.
Xtandi, developed by Astellas and Pfizer, generated $5.9 billion in sales in 2024, while Novartis’s Pluvicto reached $1.4 billion in sales during the same period.
ATNM-400 is being developed as a potential monotherapy or for use in combination with existing prostate cancer treatments. The company reports the therapy shows consistent tumor uptake with rapid clearance from blood and vital organs.
The information in this article is based on a press release statement from Actinium Pharmaceuticals.
In other recent news, Actinium Pharmaceuticals has reported promising preclinical results for its prostate cancer treatment candidate, ATNM-400. The data, presented at the American Association for Cancer Research Annual Meeting, showed a 99.8% tumor growth inhibition in prostate cancer models. This novel therapy targets a non-PSMA receptor and has demonstrated significant antitumor activity in models resistant to existing treatments like Pluvicto. Actinium is advancing ATNM-400 with plans to release more data later this year. The company has also secured a supply of the radioisotope Actinium-225 from Eckert & Ziegler to support its clinical trials. Additionally, H.C. Wainwright has maintained a Buy rating on Actinium, highlighting the company’s strong financial position and potential market opportunities. Actinium’s clinical pipeline includes trials for other cancer types, leveraging its portfolio of patents and proprietary technologies. The company remains committed to improving patient outcomes through its targeted radiotherapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.